Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Human Papillomavirus
Scientists at University of Charleston discuss research in human papillomavirus
June 2nd, 2009
According to recent research published in the journal Annals of Pharmacotherapy, "The human papillomavirus (HPV) quadrivalent vaccine was licensed in 2006 for prevention of cervical, vulvar, and vaginal cancers caused by HPV-16 and -18 and genital warts caused by HPV-6 and -11. It is also indicated for prevention of precancerous and dysplastic lesions caused by HPV-6, -11, -16, and -18." "Questions exist about the number of women and girls infected with the HPV strains covered by the vaccine, as well as about the vaccine's cost-effectiveness. There are also concerns about the efficacy of the vaccine in girls and young women, the population impact of the vaccine,...
Source: Cancer Weekly (2009-06-02)
|
